Christopher Downs - 29 Mar 2023 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)

Quoteable Key Fact

"Christopher Downs filed Form 4 for CNS Pharmaceuticals, Inc. (CNSP) on 31 Mar 2023."

Quick Takeaways

This page summarizes Christopher Downs's Form 4 filing for CNS Pharmaceuticals, Inc. (CNSP).
1 reported transaction and 1 derivative row are listed below.
Filing timestamp: 31 Mar 2023, 19:28.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CNSP transaction Derivative

Award

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one shares of Issuer common stock.
F2	The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 50% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $6.00 (subject to pro rata adjustment for stock splits or similar events); and (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $24.00 (subject to pro rata adjustment for stock splits or similar events).
F3	Issued in connection with the reporting person's employment with the Company.